Hardcover. Zustand: Good. No Jacket. Pages can have notes/highlighting. Spine may show signs of wear. ~ ThriftBooks: Read More, Spend Less.
Anbieter: ThriftBooks-Atlanta, AUSTELL, GA, USA
Hardcover. Zustand: Good. No Jacket. Pages can have notes/highlighting. Spine may show signs of wear. ~ ThriftBooks: Read More, Spend Less.
Anbieter: medimops, Berlin, Deutschland
Zustand: good. Befriedigend/Good: Durchschnittlich erhaltenes Buch bzw. Schutzumschlag mit Gebrauchsspuren, aber vollständigen Seiten. / Describes the average WORN book or dust jacket that has all the pages present.
Sprache: Englisch
Verlag: American Association of Pharmaceutical Scientists, 2005
ISBN 10: 0971176795 ISBN 13: 9780971176799
Anbieter: Romtrade Corp., STERLING HEIGHTS, MI, USA
Zustand: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.
Anbieter: BooksRun, Philadelphia, PA, USA
Hardcover. Zustand: Very Good. 2006. It's a well-cared-for item that has seen limited use. The item may show minor signs of wear. All the text is legible, with all pages included. It may have slight markings and/or highlighting.
Sprache: Englisch
Verlag: American Association of Pharmaceutical Scientists, 2005
ISBN 10: 0971176795 ISBN 13: 9780971176799
Anbieter: Majestic Books, Hounslow, Vereinigtes Königreich
EUR 164,54
Anzahl: 1 verfügbar
In den WarenkorbZustand: New. pp. xiii + 482 Illus.
Anbieter: Revaluation Books, Exeter, Vereinigtes Königreich
EUR 206,31
Anzahl: 2 verfügbar
In den WarenkorbHardcover. Zustand: Brand New. 1st edition. 586 pages. 10.00x6.50x1.50 inches. In Stock.
Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes Königreich
EUR 219,15
Anzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: New. In.
Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes Königreich
EUR 223,21
Anzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: New. In.
Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes Königreich
EUR 223,21
Anzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: New. In.
Anbieter: PsychoBabel & Skoob Books, Didcot, Vereinigtes Königreich
EUR 232,03
Anzahl: 1 verfügbar
In den WarenkorbHardcover. Zustand: Very Good. Hardcover (no jacket; printed boards). Includes CD-ROM on inside rear board. Very good condition. Half-title page has partially separated from binding. Boards' leading corners are a little bumped and scuffed. Pages are clear. TA. Used.
Anbieter: preigu, Osnabrück, Deutschland
Taschenbuch. Zustand: Neu. Optimizing the "Drug-Like" Properties of Leads in Drug Discovery | Ronald Borchardt (u. a.) | Taschenbuch | x | Englisch | 2016 | Springer US | EAN 9781493950478 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.
Buch. Zustand: Neu. Neuware - Focused on central nervous system (CNS) drug discovery efforts, this book educates drug researchers about the blood-brain barrier (BBB) so they can affect important improvements in one of the most significant - and most challenging - areas of drug discovery.\* Written by world experts to provide practical solutions to increase brain penetration or minimize CNS side-effects\* Reviews state-of-the-art in silico, in vitro, and in vivo tools to assess brain penetration and advanced CNS drug delivery strategies\* Covers BBB physiology, medicinal chemistry design principles, free drug hypothesis for the BBB, and transport mechanisms including passive diffusion, uptake/efflux transporters, and receptor-mediated processes\* Highlights the advances in modelling BBB pharmacokinetics and dynamics relationships (PK/PD) and physiologically-based pharmacokinetics (PBPK)\* Discusses case studies of successful CNS and non-CNS drugs, lessons learned and paths to the market.
Sprache: Englisch
Verlag: Springer New York, Springer US, 2016
ISBN 10: 1493950479 ISBN 13: 9781493950478
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Drug discovery and development is a very complex, costly, and ti- consuming process. Because of the uncertainties associated with predicting the pharmacological effects and the toxicity characteristics of new chemical entities in man, their clinical development is quite prone to failure. In recent years, phar- ceutical companies have come under increasing pressure to introduce new blockbuster drugs into the marketplace more rapidly. Companies have responded to these pressures by introducing new technologies and new strategies to expedite drug discovery and development. Drug discovery and development have traditionally been divided into three separate processes (i. e. , discovery research, preclinical development, and clinical development) that ideally should be integrated both organizationally and functionally. Instead, separate and distinct discovery research, preclinical development, and clinical development divisions were created within many companies during the 1980s and 1990s, Because of their isolation, scientists in the discovery research divisions often were advancing drug candidates into preclinical development that had marginal drug-like properties. For the purpose of this presentation, 'drug-like' properties refer to the molecule's physicochemical, absorption-distribution-metabolism-excretion (ADME), and toxicological properties. Lacking optimal drug-like properties often caused these drug candidates to fail in preclinical or clinical development.
EUR 234,97
Anzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: New.
Sprache: Englisch
Verlag: Springer New York, Springer New York, 2006
ISBN 10: 0387340564 ISBN 13: 9780387340562
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Drug discovery and development is a very complex, costly, and ti- consuming process. Because of the uncertainties associated with predicting the pharmacological effects and the toxicity characteristics of new chemical entities in man, their clinical development is quite prone to failure. In recent years, phar- ceutical companies have come under increasing pressure to introduce new blockbuster drugs into the marketplace more rapidly. Companies have responded to these pressures by introducing new technologies and new strategies to expedite drug discovery and development. Drug discovery and development have traditionally been divided into three separate processes (i. e. , discovery research, preclinical development, and clinical development) that ideally should be integrated both organizationally and functionally. Instead, separate and distinct discovery research, preclinical development, and clinical development divisions were created within many companies during the 1980s and 1990s, Because of their isolation, scientists in the discovery research divisions often were advancing drug candidates into preclinical development that had marginal drug-like properties. For the purpose of this presentation, 'drug-like' properties refer to the molecule's physicochemical, absorption-distribution-metabolism-excretion (ADME), and toxicological properties. Lacking optimal drug-like properties often caused these drug candidates to fail in preclinical or clinical development.
Sprache: Englisch
Verlag: American Assoc. of Pharm. Scientists, 2005
ISBN 10: 0971176795 ISBN 13: 9780971176799
Anbieter: moluna, Greven, Deutschland
Gebunden. Zustand: New. Explores ways to increase the efficiency of drug discovery and developmentThis volume focuses on how to increase the efficiency of drug discovery and development. It is written by experienced discovery scientists from diverse disciplines, including c.
Sprache: Englisch
Verlag: Amer Assn of Pharmaceutical, 2006
ISBN 10: 0387340564 ISBN 13: 9780387340562
Anbieter: Revaluation Books, Exeter, Vereinigtes Königreich
EUR 302,03
Anzahl: 2 verfügbar
In den WarenkorbHardcover. Zustand: Brand New. 1st hardback/cd-rom edition. 512 pages. 10.00x7.00x1.25 inches. In Stock.
Sprache: Englisch
Verlag: Amer Assn of Pharmaceutical, 2004
ISBN 10: 0971176795 ISBN 13: 9780971176799
Anbieter: Revaluation Books, Exeter, Vereinigtes Königreich
EUR 341,98
Anzahl: 2 verfügbar
In den WarenkorbHardcover. Zustand: Brand New. 495 pages. 10.00x7.00x1.25 inches. In Stock.
Sprache: Englisch
Verlag: American Association of Pharmaceutical Scientists, 2005
ISBN 10: 0971176795 ISBN 13: 9780971176799
Anbieter: Kennys Bookstore, Olney, MD, USA
Zustand: New. Editor(s): Borchardt, Ronald; Kerns, Edward H.; Lipinski, Christopher A.; Thakker, Dhrien R.; Wang, Binghe. Series: Biotechnology: Pharmaceutical Aspects. Num Pages: 482 pages, 121 black & white illustrations, 9 colour illustrations, 47 black & white tables, biograp. BIC Classification: MBGR1. Category: (P) Professional & Vocational. Dimension: 254 x 178 x 33. Weight in Grams: 1237. . 2005. 2004th Edition. hardcover. . . . . Books ship from the US and Ireland.
Sprache: Englisch
Verlag: American Association Of Pharmaceuticals Scientists Dez 2005, 2005
ISBN 10: 0971176795 ISBN 13: 9780971176799
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Buch. Zustand: Neu. Neuware - At a time when pharmaceutical companies have limited resources to develop newer and better drugs, they must continually evaluate the effectiveness and efficiency of their research and development process. This volume focuses on how to increase the efficiency of drug discovery and development. Written by experienced discovery scientists from diverse disciplines, including chemistry, drug metabolism, and development sciences, it details in silico, in vitro, and in vivo tools for prediction, measurement, and application of compound properties to select and improve potential drug candidates.